Simplify + speed up your trials.
  • Everything in one place
  • Seamless, scalable and efficient
  • High quality data
Your form has been received!

Thank you for your interest in Medable. We will be in touch with you shortly.

In the meantime, read more about Medable’s Enterprise Solutions:

Blog posts
6 min
Medable perspective: Key takeaways of recent FDA DCT Draft Guidance
No items found.
Done
Please fill out the form to read this article
Platform
Back
  • Overview
  • Total Consent
  • eCOA + ePRO
Solutions
Back
By therapeutic area
  • Overview
  • Oncology
  • Vaccine
By business type
  • Mid to Large Pharma
  • Emerging BioPharma
  • CRO
Resources
Back
  • Knowledge Center
  • Events
  • Medable Academy
  • FAQ
Company
Back
  • About
  • Newsroom
  • Careers
  • Contact
  • Support
Book a Demo

Progressing BYOD Adoption

Perspectives
6 min

Access this article by answering a few questions

Unlock this article now

Related articles

See all
Perspectives

Gender equity relies on health equity

6 min

By Sanskriti (“Sans”) Thakur, CGO. As we celebrate Women’s History Month this March, the world takes a moment to recognise women’s accomplishments, while also highlighting the inequity that remains. When it comes to women’s health, those inequities are stark. And a contributing factor is the lack of women in clinical trials. When population representation falls short, medicines are less safe and effective. Measures such as the US Congress’s proposed DIVERSE Trials Act are helping drive equitable representation, but that’s just the beginning.

Perspectives

Population Representation: Everyone Must Play a Part

6 min

By Hady Khoury, Chief Development Officer, Medable. The life sciences industry has been talking about improving diversity in clinical trials for years. Historically, this talk has amounted to a lot of hot air. But the situation is urgent: while racial and ethnic minorities comprise nearly 40% of the US population, they only account for 2% to 16% of clinical trial participation. Within oncology, Black Americans constitute around 22% of cancer cases, but less than 5% of trial enrollees. This isn’t just a US issue; globally, 76% of patients enrolled in oncology trials are white. And this challenge exists within a research landscape where nearly 80% of trials fall short of enrollment targets to begin with.

‍

‍

Perspectives

ACRP: Unique Considerations for Patient Retention in Decentralized Clinical Trials

6 min

By Ingrid Oakley-Girvan, PhD, SVP, Value and Strategy. As decentralized clinical trials (DCTs) become more prevalent, particularly in the wake of the pandemic, their lower burden approach can make participation more attractive for some. Yet the vexing issue of retaining participants throughout the course of a trial will continue to be problematic without a thoughtful approach to keep them engaged. A three-phase model of engagement, based on proven science and intelligently informed by utilizing data, can make important inroads into solving this long-standing challenge.

See how Medable can make your trials more efficient.

Book a demo

Unified clinical trials.

Platform

  • Overview
  • Total Consent
  • eCOA + ePRO

Solutions

By Therapeutic Area

  • Overview
  • Oncology
  • Vaccine

By Business type

  • Mid to Large Pharma
  • Emerging BioPharma
  • CRO

Resources

  • Knowledge Center
  • Events
  • FAQ

Company

  • About
  • Newsroom
  • Careers
  • Contact
  • Support
PrivacyLegalTerms of UseDo not sell or share my personal information

© 2023 Medable Inc. All rights Reserved